In conclusion, our data demonstrate that upregulation of select PDI family members can be considered as risk factors for ovarian cancer patients and PDI, PDIR, ERp57, ERp72 and AGR3 could be used as prognostic biomarkers. This evidence concerns the gene PDIA3 and ovarian carcinoma.